Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer

BACKGROUND: Resected HER2 breast cancer patients treated with adjuvant trastuzumab and chemotherapy have superior survival compared to patients treated with chemotherapy alone. We previously showed that trastuzumab and chemotherapy induce HER2-specific antibodies which correlate with improved surviv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res
Main Authors: Norton, Nadine, Fox, Nicholas, McCarl, Christie-Ann, Tenner, Kathleen S., Ballman, Karla, Erskine, Courtney L., Necela, Brian M., Northfelt, Donald, Tan, Winston W., Calfa, Carmen, Pegram, Mark, Colon-Otero, Gerardo, Perez, Edith A., Clynes, Raphael, Knutson, Keith L.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6000975/
https://ncbi.nlm.nih.gov/pubmed/29898752
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-018-0989-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados